Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 363 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Overactive Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Implantable Tibial Neuromodulation (TITAN 1) Feasibility Study

NCT04873271
View directory record Official record
Conditions
Overactive Bladder
Interventions
Medtronic Implantable Tibial Neuromodulation (TNM) System
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
7
States / cities
Marietta, Georgia • Englewood, New Jersey • Hamlet, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Oct 22, 2026, 10:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microbiomes of Pelvic Pain

NCT01738464
View directory record Official record
Conditions
Interstitial Cystitis, Chronic Prostatitis, Chronic Pelvic Pain Syndrome, Lower Urinary Tract Symptoms, Overactive Bladder, Major Depression
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 22, 2026, 10:45 AM EDT
Completed No phase listed Observational Results available

Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder

NCT03033355
View directory record Official record
Conditions
Multiple Sclerosis, Lower Urinary Tract Symptoms, Neurogenic Bladder, Detrusor, Overactive, Urge Incontinence
Interventions
Intra-detrusor injection of Onabotulinumtoxin-A
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 22, 2026, 10:45 AM EDT
Recruiting Phase 4 Interventional

Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A

NCT04305743
View directory record Official record
Conditions
Urinary Bladder, Overactive, Incontinence, Urge, Incontinence, Urinary, Urinary Urge Incontinence, Urinary Frequency More Than Once at Night, Nocturia
Interventions
OnabotulinumtoxinA 100 UNT
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 22, 2026, 10:45 AM EDT
Completed Phase 4 Interventional Results available

Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life

NCT00573508
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Placebo, Solifenacin Succinate
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
59
States / cities
Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2010 · Synced Oct 22, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.

NCT04534491
View directory record Official record
Conditions
Overactive Bladder
Interventions
Oxybutynin (Oxytrol, BAY839380)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Saint Joseph, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 22, 2026, 10:45 AM EDT
Not listed Not applicable Interventional

Electrical Nerve Stimulation for Overactive Bladder a Comparison of Treatments

NCT01940367
View directory record Official record
Conditions
Overactive Bladder, Urge Urinary Incontinence
Interventions
PTNS (Percutaneous Tibial Nerve Stimulation, TENS (Transcutaneous Electrical Nerve Stimulation)
Device
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Bethesda, Maryland • Fort Belvoir, Virginia • Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 22, 2026, 10:45 AM EDT
Completed No phase listed Observational

Vaginal Electrical Stimulation Versus Neuromodulation

NCT01525485
View directory record Official record
Conditions
Refractory Overactive Bladder
Interventions
Not listed
Lead sponsor
University of Oklahoma
Other
Eligibility
21 Years to 99 Years · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Oct 22, 2026, 10:45 AM EDT
Not listed Not applicable Interventional

The Use of cineMRI to Evaluate Botox in Patients With Medication Refractory Overactive Bladder

NCT02315950
View directory record Official record
Conditions
Overactive Bladder
Interventions
Botulinum toxin and cineMRI-UDS
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
21 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency

NCT01294982
View directory record Official record
Conditions
Overactive Bladder
Interventions
AOBO-001, Placebo
Drug
Lead sponsor
American Oriental Bioengineering, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Mobile, Alabama • West Palm Beach, Florida • Newton, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 22, 2026, 10:45 AM EDT
Completed No phase listed Observational

Overactive Bladder (OAB) Voiding Diary and Urodynamics Correlation Study

NCT03473782
View directory record Official record
Conditions
Overactive Bladder
Interventions
Voiding Diary, Urodynamics Correlation Study
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 110 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Oct 22, 2026, 10:45 AM EDT
Terminated Phase 4 Interventional Results available

Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection

NCT03508921
View directory record Official record
Conditions
Overactive Bladder, Urinary Tract Infections
Interventions
Periprocedural Antibiotics, Extended Antibiotics, Injection of OnabotulinumtoxinA (BTX-A)
Drug · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 22, 2026, 10:45 AM EDT
Completed Not applicable Interventional Results available

Impact of Decision Aids in Urogynecology

NCT04369404
View directory record Official record
Conditions
Pelvic Organ Prolapse, Stress Urinary Incontinence, Overactive Bladder
Interventions
Pelvic organ prolapse decision aid, Stress urinary incontinence decision aid, Overactive bladder decision aid
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 95 Years · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 22, 2026, 10:45 AM EDT
Recruiting Not applicable Interventional

Fluoroscopy Radiation Reduction During Sacral Neuromodulation Lead Placement

NCT04527445
View directory record Official record
Conditions
Radiation Exposure, Overactive Bladder, Urge Incontinence, Urgency-frequency Syndrome
Interventions
Reduced radiation fluoroscopy, Conventional fluoroscopy
Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 89 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 22, 2026, 10:45 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Stress and Anxiety Effects on Overactive Bladder

NCT05087810
View directory record Official record
Conditions
Overactive Bladder, Stress, Psychological, Anxiety
Interventions
Psychological stress induction, Accelerated oral hydration
Behavioral · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 22, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cyclic Versus Continuous Sacral Neuromodulation for LUTS

NCT06170450
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Cyclic SNM, Continuous SNM
Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Louisville, Kentucky • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 22, 2026, 10:45 AM EDT
Completed Phase 4 Interventional Results available

Trospium Chloride XR in Obese Female Patients With Overactive Bladder

NCT00932022
View directory record Official record
Conditions
Obesity, Overactive Bladder, Incontinence
Interventions
Trospium Chloride, Extended Release (XR), placebo
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
La Mesa, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2013 · Synced Oct 22, 2026, 10:45 AM EDT
Completed Phase 4 Interventional Results available

Overactive Bladder Innovative Therapy Trial (OrBIT)

NCT00448175
View directory record Official record
Conditions
Overactive Bladder
Interventions
Urgent PC Neuromodulation System, Tolterodine
Device · Drug
Lead sponsor
Uroplasty, Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minnetonka, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Oct 22, 2026, 10:45 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Xeomin vs Botox for Treatment of Overactive Bladder Syndrome

NCT06034288
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Xeomin 100 UNT Injection, Botox 100 UNT Injection
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 22, 2026, 10:45 AM EDT
Completed Not applicable Interventional

FemPulse Therapy for Overactive Bladder in Women

NCT03784170
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
FemPulse System
Device
Lead sponsor
FemPulse Corporation
Industry
Eligibility
21 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Woodbury, Minnesota • Charlotte, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 22, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

NCT01908829
View directory record Official record
Conditions
Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
Interventions
mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo, mirabegron 50 mg matching placebo, solifenacin 5 mg matching placebo, solifenacin 10 mg matching placebo
Drug
Lead sponsor
Astellas Pharma Europe Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
36
States / cities
Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 22, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects

NCT00703703
View directory record Official record
Conditions
Healthy
Interventions
Darifenacin, Tolterodine, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
21
States / cities
Phoenix, Arizona • Tempe, Arizona • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 22, 2026, 10:45 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder

NCT01192568
View directory record Official record
Conditions
Overactive Detrusor, Neurogenic Bladder
Interventions
Oxybutynin, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
3 Years to 16 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
10
States / cities
Loma Linda, California • Orange, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 22, 2026, 10:45 AM EDT
Completed Phase 4 Interventional Results available

OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder

NCT01945489
View directory record Official record
Conditions
Overactive Bladder
Interventions
onabotulinumtoxinA, Normal saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
40
States / cities
Huntsville, Alabama • Anchorage, Alaska • Laguna Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 22, 2026, 10:45 AM EDT